Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

One UK Notified Body To Be Phased Out This Year As It Moves To Sweden

Executive Summary

Notified bodies are busy repositioning themselves this year in the light of Brexit. One UK notified body is relocating to Sweden, but it is playing down Brexit and emphasizing the benefits of centralization.

You may also be interested in...



UK Brexit White Paper Would Keep Medtech Regulatory System – And Testing Just Once – Intact

It looks as if the EU medtech regulatory system could survive intact in the UK, given terms of the UK blueprint for its future relationship with the EU after separation. But a storm of controversy must be navigated first.

UK Outlook 2018: IVDs Faces Up To Digital, Pathology Consolidation And IVDR Challenges

UK diagnostics manufacturers face major challenges in adapting to the EU IVDR and to the possible changes that Brexit will bring in regulation, trading conditions, costs and access to talent. In addition, the industry will have to factor in a restructuring of pathology networks and future NHS procurement changes, all while transitioning to digital health-care concepts, says IVD industry association chief Doris-Ann Williams.

EU Regulatory Experts Support Notified Bodies, But Argue For Greater Consistency

Notified bodies have been a pivotal part of the EU medtech regulatory system since it was first launched in the 1990s. Where might they fit within a new medtech regulatory governance structure? Panelists on a recent vodcast grappled with the question.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT122235

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel